AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.

AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He ...

At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma.

AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver ...

The approval relies on positive data from the POTOMAC Phase III trial.

Is AZN a good stock to buy? We came across a bullish thesis on AstraZeneca PLC on South Sea Investing’s Substack. In this article, we will summarize the bulls’ thesis on AZN. AstraZeneca PLC’s share ...

AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...

Private equity firm CVC Capital Partners and Groupe Bruxelles Lambert launched a $12.4 billion takeover bid for Recordati. Eli Lilly announced plans to acquire three early and mid-stage vaccine ...

AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...

AstraZeneca (LSE:AZN) received US FDA approval for IMFINZI (durvalumab) with BCG therapy in BCG naïve, high risk non muscle invasive bladder cancer, based on positive Phase III data showing a ...

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of ...

TESTS. EXPERTS HERE AT THE UNIVERSITY OF MARYLAND SAY EARLY DETECTION CAN HAVE A BIGGER IMPACT ON A PATIENT’S CHANCE OF SURVIVAL THAN IMMUNOTHERAPY AND CHEMOTHERAPY. I’M SMOKE FREE FOR SIX MONTHS NOW, ...